Zoetis Inc. $ZTS Shares Sold by Berkeley Inc

Key Points

• Berkeley Inc cut its stake in Zoetis by 61.2% in Q4, selling 32,022 shares and retaining 20,295 shares worth $2.554 million at quarter-end.
• Analyst sentiment is mixed with an average rating of "Hold" (7 Buy, 7 Hold, 1 Sell) and an average target of $152.25; recent notable moves include a downgrade by Weiss and an upgrade by Wall Street Zen, while Piper Sandler cut its price target to $135 from $190.
• Zoetis beat the quarter's expectations (EPS $1.48 vs. $1.40 consensus; revenue $2.39B vs. $2.36B), set FY2026 guidance of $7.00–$7.10 EPS, and announced a $0.53 quarterly dividend ($2.12 annualized, ~1.8% yield).

Berkeley Inc cut its stake in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 61.2% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 20,295 shares of the company's stock after selling 32,022 shares during the period. Berkeley Inc's holdings in Zoetis were worth $2,554,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Brighton Jones LLC grew its holdings in shares of Zoetis by 180.4% during the fourth quarter. Brighton Jones LLC now owns 4,629 shares of the company's stock worth $754,000 after buying an additional 2,978 shares in the last quarter. Empowered Funds LLC grew its holdings in shares of Zoetis by 6.2% during the first quarter. Empowered Funds LLC now owns 11,293 shares of the company's stock worth $1,859,000 after buying an additional 657 shares in the last quarter. Intech Investment Management LLC grew its holdings in shares of Zoetis by 17.2% during the first quarter. Intech Investment Management LLC now owns 8,347 shares of the company's stock worth $1,374,000 after buying an additional 1,224 shares in the last quarter. Sivia Capital Partners LLC grew its holdings in shares of Zoetis by 73.8% during the second quarter. Sivia Capital Partners LLC now owns 3,348 shares of the company's stock worth $522,000 after buying an additional 1,422 shares in the last quarter. Finally, Glenview Trust co grew its holdings in shares of Zoetis by 11.8% during the second quarter. Glenview Trust co now owns 4,780 shares of the company's stock worth $745,000 after buying an additional 506 shares in the last quarter. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. Weiss Ratings lowered shares of Zoetis from a "hold (c-)" rating to a "sell (d+)" rating in a report on Friday, March 27th. Morgan Stanley set a $160.00 target price on shares of Zoetis in a report on Thursday, December 18th. Wall Street Zen raised shares of Zoetis from a "hold" rating to a "buy" rating in a report on Saturday, February 21st. BTIG Research reaffirmed a "buy" rating and set a $160.00 target price on shares of Zoetis in a report on Thursday, February 26th. Finally, Piper Sandler reissued a "neutral" rating and issued a $135.00 price objective (down from $190.00) on shares of Zoetis in a report on Thursday, January 22nd. Seven research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $152.25.

Zoetis Stock Performance

Shares of Zoetis stock opened at $119.15 on Friday. The firm has a market cap of $50.12 billion, a PE ratio of 19.79, a price-to-earnings-growth ratio of 1.84 and a beta of 0.98. The company has a quick ratio of 1.94, a current ratio of 3.03 and a debt-to-equity ratio of 2.71. Zoetis Inc. has a 52 week low of $113.29 and a 52 week high of $172.23. The business's fifty day simple moving average is $121.83 and its 200-day simple moving average is $126.65.

Zoetis (NYSE:ZTS - Get Free Report) last issued its quarterly earnings data on Thursday, February 12th. The company reported $1.48 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.40 by $0.08. The firm had revenue of $2.39 billion during the quarter, compared to the consensus estimate of $2.36 billion. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The company's quarterly revenue was up 3.0% on a year-over-year basis. During the same period last year, the company earned $1.40 EPS. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. Equities analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 2nd. Shareholders of record on Monday, April 20th will be paid a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a yield of 1.8%. The ex-dividend date of this dividend is Monday, April 20th. Zoetis's dividend payout ratio (DPR) is 35.22%.

Zoetis Profile

Zoetis Inc NYSE: ZTS is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company's offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.